Robotic uro-oncology applications of the SSI Mantra™ surgical robotic system

Abstract

Objective

To report our preliminary clinical experience and outcomes of uro-oncology procedures conducted utilizing the SSI Mantra™ surgical robotic system.

Methods

Data of consecutive patients who underwent various robot-assisted uro-oncology procedures using the SSI Mantra™ surgical robotic system at our institution between July 2022 and September 2023 were recorded. The specific surgical configurations employed with the SSI Mantra™ for these procedures were duly noted. We assessed the feasibility of these procedures with this novel surgical robotic system and report the outcomes.

Results

A total of 156 patients were operated with the SSI Mantra™ surgical robotic system. The spectrum of procedures performed comprised robot-assisted laparoscopic radical prostatectomy with bilateral extended pelvic lymph node dissection (n=77), robot-assisted radical cystectomy with bilateral extended pelvic lymph node dissection with extracorporeal urinary diversion (n=39), robot-assisted radical nephrectomy (n=32), robot-assisted partial nephrectomy (n=6), robot-assisted radical nephroureterectomy with bladder cuff excision (n=1), and bilateral robot-assisted video endoscopic inguinal lymph node dissection (n=1). One robot-assisted laparoscopic radical prostatectomy had to be converted to open in view of system malfunction. However, no system-related intraoperative complications or injuries were encountered.

Conclusion

The SSI Mantra™ surgical robotic system demonstrates significant promise as an innovative robotic platform. In this single-center experience, we have demonstrated the feasibility of a diverse array of surgical procedures using this platform. Further research, involving a larger cohort of patients, is imperative to refine the operative techniques and comprehensively understand the perioperative outcomes of the SSI Mantra™ surgical robotic system, particularly in comparison to other robotic surgical platforms.